Latest News and Press Releases

STOCKHOLM, SVERIGE 9 april 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att den amerikanska läkemedelsmyndigheten FDA har beviljat särläkemedelsstatus för Aprea Therapeutics...

STOCKHOLM, SWEDEN – April 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Aprea...

STOCKHOLM, SVERIGE 6 april 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Dilafor har slutfört inklusionen av patienter till sin studie av tafoxiparin – en...

STOCKHOLM, SWEDEN – April 6, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Dilafor has completed the inclusion of patients to its study of...

Aktieägarna i Karolinska Development AB (publ), org.nr 556707-5048, (“Karolinska Development” eller “Bolaget”), kallas till årsstämma onsdagen den 5 maj 2021. Med anledning av den fortsatta...

The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Annual General Meeting, on Wednesday May 5, 2021. Due to...

STOCKHOLM, SVERIGE 25 mars 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att årsredovisningen för 2020 har offentliggjorts. Årsredovisningen finns nu tillgänglig på...

STOCKHOLM, SWEDEN – March 25, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2020. The report is now available to download at...

STOCKHOLM, SVERIGE 15 mars 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics förbereder en notering på Nasdaq First North Growth Market...

STOCKHOLM, SWEDEN – March 15, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics is preparing a listing on Nasdaq First North Growth...